AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Vicore Pharma Holding Share Issue/Capital Change 2022

Dec 30, 2022

3211_rns_2022-12-30_f18284b6-043a-4e0e-bd42-b593f70cf6bb.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Increase of number of shares and votes in Vicore Pharma

Stockholm, December 30, 2022– Vicore Pharma Holding AB (publ) ("Vicore" or the "company")'s registered share capital and number of outstanding shares and votes have increased during the month of December 2022.

As previously announced, the company's board of directors resolved on a directed share issue of 10,000,000 shares at a subscription price of SEK 20.00 per share on December 8, 2022. Through the share issue, Vicore received issue proceeds of 200 MSEK before issue costs.

As of today, the total number of registered and outstanding shares and votes of Vicore amounts to 81,847,979. Furthermore, the registered share capital amounts to SEK 40,923,989.10.

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, [email protected] Hans Jeppsson, CFO, tel: +46 70 553 14 65, [email protected]

This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on December 30, 2022, at 09:00 CEST.

About Vicore Pharma Holding AB (publ)

Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary artery hypertension (PAH). VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for PF patients.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.